Amanda Cole
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amanda Cole has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Ali Y. Suliman
Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, USA
1 shared publication - Amber Davis
Department of Infectious Diseases St. Jude Children's Research Hospital Memphis Tennessee USA
1 shared publication Ashleigh Gowen
Department of Infectious Diseases St. Jude Children's Research Hospital Memphis Tennessee USA
1 shared publication- Brandon Matthew Triplett
Department of Bone Marrow Transplantation and Cellular Therapy St. Jude Children's Research Hospital Memphis Tennessee USA
1 shared publication - Diego Raul Hijano
Department of Infectious Diseases, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
1 shared publication - Dinesh Keerthi
Department of Bone Marrow Transplantation and Cellular Therapy St. Jude Children's Research Hospital Memphis Tennessee USA
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9) , e70467
Role of Respiratory Viral Infections in Airflow Obstruction After Hematopoietic Cell Transplantation
Background: Respiratory viral infections (RVIs) in allogeneic hematopoietic cell transplant (allo‐HCT) recipients can cause airflow obstruction (AFO). Despite this risk, the impact of community‐acquired RVI on PFTs in pediatric patients after allo‐HCT remains unclear. Objective: The study determines the role of RVI in the development of AFO post‐transplant among survivors of allo‐HCT. Study Design: This retrospective study analyzed St. Jude patients undergoing allo‐HCT between 2003–2020. AFO was defined by z ‐scores and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio expressed as lower limit of normal (LLN). Baseline parameters were obtained before allo‐HCT, and Year 1 parameters within 425 days post allo‐HCT. Spirometry measures were calculated using the global lung function Initiative (GLI) calculator. Bivariate and multivariate logistic regression identified risk factors for AFO following allo‐HCT. Results: A total of 397 patients were included, with a median age of 12.7 years. RVI occurred in 13% of patients within the first 100 days after transplantation. AFO developed in 12% of patients. Among those with AFO, 68% had a baseline FEV1/FVC ratio above the LLN, and 11% had a history of lower respiratory tract infection (LRTI) ( p < 0.05). The median time from transplant to RVI was shorter in patients with AFO (12 vs. 34 days). A baseline LLN value was a significant predictor of AFO. However, after adjusting for known covariates, RVI was not independently associated with AFO risk. Conclusion: RVIs within 100 days of allo‐HCT did not significantly affect AFO following transplant in pediatric patients.
- 25 September 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (9) , e70467
Open AccessRole of Respiratory Viral Infections in Airflow Obstruction After Hematopoietic Cell Transplantation
Background: Respiratory viral infections (RVIs) in allogeneic hematopoietic cell transplant (allo‐HCT) recipients can cause airflow obstruction (AFO). Despite this risk, the impact of community‐acquired RVI on PFTs in pediatric patients after allo‐HCT remains unclear. Objective: The study determines the role of RVI in the development of AFO post‐transplant among survivors of allo‐HCT. Study Design: This retrospective study analyzed St. Jude patients undergoing allo‐HCT between 2003–2020. AFO was defined by z ‐scores and forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio expressed as lower limit of normal (LLN). Baseline parameters were obtained before allo‐HCT, and Year 1 parameters within 425 days post allo‐HCT. Spirometry measures were calculated using the global lung function Initiative (GLI) calculator. Bivariate and multivariate logistic regression identified risk factors for AFO following allo‐HCT. Results: A total of 397 patients were included, with a median age of 12.7 years. RVI occurred in 13% of patients within the first 100 days after transplantation. AFO developed in 12% of patients. Among those with AFO, 68% had a baseline FEV1/FVC ratio above the LLN, and 11% had a history of lower respiratory tract infection (LRTI) ( p < 0.05). The median time from transplant to RVI was shorter in patients with AFO (12 vs. 34 days). A baseline LLN value was a significant predictor of AFO. However, after adjusting for known covariates, RVI was not independently associated with AFO risk. Conclusion: RVIs within 100 days of allo‐HCT did not significantly affect AFO following transplant in pediatric patients.